Anti-Amyloid Beta Reference Antibody (solanezumab)

[APP; APP; AAA; AD1; PN2; ABPP; APPI; CVAP; ABETA; PN-II; CTFgamma; A4; AD1; APP; CVAP; PN-II; S-APP-alpha; S-APP-beta; AICD-59; AID(59); AICD-57; AID(57); AICD-50; AID(50)]

[amyloid beta A4 protein isoform a; Amyloid beta A4 protein; amyloid beta A4 protein; preA4; protease nexin-II; peptidase nexin-II; beta-amyloid peptide; alzheimer disease amyloid protein; cerebral vascular amyloid peptide; amyloid beta (A4) precursor protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-IICleaved into the following 14 chains:N-APPSoluble APP-alpha; S-APP-alphaSoluble APP-beta; S-APP-betaC99Beta-amyloid protein 42; Alternative name(s):; Beta-APP42Beta-amyloid protein 40; Alternative name(s):; Beta-APP40C83P3(42)P3(40)C80Gamma-secretase C-terminal fragment 59; Alternative name(s):; Amyloid intracellular domain 59; AICD-59; AID(59); Gamma-CTF(59)Gamma-secretase C-terminal fragment 57; Alternative name(s):; Amyloid intracellular domain 57; AICD-57; AID(57); Gamma-CTF(57)Gamma-secretase C-terminal fragment 50; Alternative name(s):; Amyloid intracellular domain 50; AICD-50; AID(50); Gamma-CTF(50)]